GW Pharmaceuticals plc: 27/01/2015 GW Pharmaceuticals to Report Q1, 2015 Financial Results and Host Conference Call on 4 February, 2015

Tickers: GWPH

January 27, 2015

GW Pharmaceuticals to Report Q1, 2015 Financial Results and Host Conference Call on 4

February, 2015

LONDON, Jan. 27, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will report on 4 February, 2015 its first quarter financial results for the period ending
31 December, 2014. GW will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT.
Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. GW is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex®, which is in Phase 2/3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc (Today) +44 20 3727 1000

Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000

Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570

FTI Consulting (Media Enquiries)

Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000

Robert Stanislaro (U.S.) 212 850 5657

Trout Group, LLC (U.S. investor relations)

Todd James / Chad Rubin 646 378 2900

Source: GW Pharmaceuticals plc
News Provided by Acquire Media

distributed by

This content was issued by GW Pharmaceuticals plc on the 2015-01-27 and was initially posted on www.gwpharm.com. It was distributed, unedited and unaltered, by noodls on 2015-02-05 14:02:50 UTC. The original issuer is solely responsible for the accuracy of the information contained therein.